<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02463851</url>
  </required_header>
  <id_info>
    <org_study_id>RDC-2014.01</org_study_id>
    <nct_id>NCT02463851</nct_id>
  </id_info>
  <brief_title>PVAC GOLD Versus Irrigated RF Single Tip Catheter With Contact FORCE Ablation of the Pulmonary Veins for Treatment of Drug Refractory Symptomatic Paroxysmal and Persistent Atrial Fibrillation</brief_title>
  <acronym>GOLD-FORCE</acronym>
  <official_title>PVAC GOLD Versus Irrigated RF Single Tip Catheter With Contact FORCE Ablation of the Pulmonary Veins for Treatment of Drug Refractory Symptomatic Paroxysmal and Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>L.V.A. Boersma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>R&amp;D Cardiologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GOLD FORCE trial investigates the differences between treatment with a Contact Force
      single-tip catheter against the PVAC GOLD multielectrode catheter in cardiac ablation
      procedures in patients with paroxysmal atrial fibrillation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants free of Atrial Fibrillation and not taking anti-arrhythmic drugs</measure>
    <time_frame>Month 3 after intervention</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>AF-Ablation with Multi-electrode catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular AF-ablation with a multi-electrode ablation catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AF-Ablation with Contact Force single-tip electrode</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular AF-ablation with a regular Contact Force single-tip ablation catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PVAC GOLD multielectrode catheter</intervention_name>
    <description>Cardiac ablation for Atrial Fibrillation</description>
    <arm_group_label>AF-Ablation with Multi-electrode catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Contact Force single-tip ablation catheter</intervention_name>
    <arm_group_label>AF-Ablation with Contact Force single-tip electrode</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. History of symptomatic paroxysmal atrial fibrillation defined as:

               -  Self-terminating AF with episodes lasting no more than seven consecutive days
                  before spontaneous conversion back to sinus rhythm

               -  Documentation of one or more events with PAF tracings by ECG, event recordings,
                  pacemaker strips or monitor rhythm strips within the past year

               -  AF symptoms defined as the manifestation of any of the following:

                    -  Palpitations

                    -  Fatigue

                    -  Exertional dyspnea

                    -  Effort intolerance

          2. Age between 18 and 70 Willingness, ability and commitment to participate in baseline
             and follow-up evaluations for the full length of the study

        Exclusion Criteria:

          1. Structural heart disease of clinical significance including:

               -  Previous cardiac surgery (excluding CABG)

               -  Symptoms of congestive heart failure including, but not limited to, NYHA Class
                  III or IV CHF and/or documented ejection fraction &lt; 40% measured by acceptable
                  cardiac testing

               -  Left atrial diameter of &gt; 45mm as measured in the parasternal long axis on
                  transthoracic echocardiogram

               -  LA volume&gt;40 ml/m2

               -  Stable/unstable angina or ongoing myocardial ischemia

               -  Myocardial infarction (MI) within three months of enrollment

               -  Aortic or mitral valve disease &gt; Grade II

               -  Congenital heart disease (not including ASD or PFO without a right to left shunt)
                  where the underlying abnormality increases the risk of an ablative procedure

               -  Prior ASD or PFO closure with a device using a percutaneous approach

               -  Hypertrophic cardiomyopathy (LV wall thickness &gt; 1.5 cm)

               -  Pulmonary hypertension (mean or systolic PA pressure &gt;50mm Hg on Doppler echo

          2. Prior ablation for arrhythmias other than AF within the past three months

          3. Prior left sided AF ablation

          4. Enrollment in any other ongoing arrhythmia study protocol Any ventricular
             tachy-arrhythmias currently being treated where the arrhythmia or the management may
             interfere with this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>L.V.A. Boersma, MD PhD</last_name>
    <phone>+31-30-6099111</phone>
    <email>l.boersma@antoniusziekenhuis.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Praxisklinik Herz und Gefäße</name>
      <address>
        <city>Dresden</city>
        <zip>D-01099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franziska Günther</last_name>
      <phone>+351-8064-442</phone>
      <email>franziska.guenther@zfkp-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Kerstin Bonin</last_name>
      <phone>+351-8064-442</phone>
      <email>kerstin.bonin@zfkp-dresden.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stephan G. Spitzer, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3534CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.A.R. Bosschaert, MD</last_name>
      <phone>+31-30-6092278</phone>
      <email>m.bosschaert@antoniusziekenhuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>Martijn Klaver, MD</last_name>
      <phone>+31-30-6092278</phone>
      <email>m.klaver@antoniusziekenhuis.nl</email>
    </contact_backup>
    <investigator>
      <last_name>L.V.A. Boersma, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8011JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Nijenbrinks</last_name>
      <phone>+31-38-4244850</phone>
    </contact>
    <contact_backup>
      <last_name>Jenny van Dekken</last_name>
      <phone>+31-38-4244850</phone>
    </contact_backup>
    <investigator>
      <last_name>Arif Elvian, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>R&amp;D Cardiologie</investigator_affiliation>
    <investigator_full_name>L.V.A. Boersma</investigator_full_name>
    <investigator_title>Cardiologist</investigator_title>
  </responsible_party>
  <keyword>Ablation</keyword>
  <keyword>Multi-electrode catheter PVAC</keyword>
  <keyword>Single-tip catheter Contact Force</keyword>
  <keyword>Holter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

